

A look at ESG in 2020: Responsibility and Resilience

The defining global challenges of last year reinforced how critical our environmental, social and governance (ESG) mindset is. Teva's renewed ESG strategy guides how we advance health and equity, minimize our impact on the planet and dedicate ourselves to quality, ethics and transparency.

Prioritized the health, safety and well-being

of our 40,000+ employees and promoted inclusion and diversity (I&D)



82% of employees feel Teva's culture promotes I&D

Best employee safety performance to date:

Total recordable injury rate

↓ **9%**

Total recordable injuries

↓ **15%**

COVID-19 response



0 COVID-19-related job losses



Committed to launch **8** access to medicines programs globally by 2025

Developed, manufactured and distributed quality medicines:



Invested **\$1B** in R&D



800 new generic marketing authorizations



Provided **3,000** medicines, reaching nearly 200M patients each day



Donated **\$571M** worth of medicines (317M units) to patients in need, 2X more than in 2019



Donated **\$30M** worth of medicines (13M units) for COVID-19 clinical studies to 26 governments and hospitals around the world

Increased access to our medicines for patients in need



Committed to reduce Scope 1 and 2 greenhouse gas emissions by **33%** by 2030 (vs. 2017)

Reduced:

Scope 1 and 2 greenhouse gas emissions by **25%** (vs. 2017)

Water withdrawal in water-stressed areas by **13%** (vs. 2019)

Total energy consumption by **6%** (vs. 2019)

Minimized our impact on the environment



Maintained supply continuity and environmental performance despite COVID-19 requirements, including reduced workforce onsite

Operated an ethical, accountable business



99.8% completion rate for Our Way of Life (OWL) ethics training



Published **7** new policies and positions, including on talent recruitment and development, pricing, quality manufacturing, compassionate use, harassment, tax and lethal injections



Adapted monitoring process for virtual healthcare professional interactions

Sustainalytics:

Top **10%** of pharmaceutical companies

Advanced our ESG performance

S&P Global:

Top **30%** of pharmaceutical companies